Scientists Find a Vulnerable Window When Brain Metastases Can Still Be Stopped

Metastasis remains the deadliest act in the theatre of cancer. When tumour cells leave their original site and seed themselves in distant organs, the disease shifts from a localised, often curable problem into a systemic one, and it is this spreading process that is linked to the majority of cancer deaths. Now, in a study published in Cancer Cell, researchers at the Spanish National Cancer Research Centre (CNIO) report the discovery of a previously unknown, transient phase in the life of a metastatic cell — a window during which the nascent colony is strikingly defenceless. The finding, validated in mice and in human tissue, suggests that brain metastases might one day be eliminated before they are even detectable, opening a realistic path toward what oncologists have long considered a distant dream: prevention.

The research, led by Manuel Valiente, head of CNIO’s Brain Metastasis Group, is the product of more than six years of work and involved more than 70 co-authors from roughly 20 institutions across Spain, the United Kingdom, Germany, France and the United States. Its central insight is deceptively simple. When cancer cells that originated in, say, a lung, breast or skin tumour arrive in the brain, they confront an environment radically different from the one they left. That new environment is so hostile that many of the arriving cells simply die during the adaptation process. But the cells that do survive, the CNIO team discovered, do not immediately resume their aggressive expansion. Instead, they enter what the authors call a proliferative pause — a period of molecular reprogramming during which the cells quietly search for ways to endure their new surroundings while temporarily abandoning the breakneck division that defines overt tumour growth.

It is during this pause that the metastatic seeds are vulnerable. The study describes the molecular machinery that underlies this period of relative inactivity, and, crucially, a way of disrupting it. When the machinery is blocked, cells within an incipient metastasis fail to adapt to their new environment and perish. “When we analysed the biology of these micrometastases, which are still clinically undetectable, we identified the molecular mechanisms that were active,” Valiente explains. “Because there are already drugs whose targets are precisely those molecules, we tested three of them in animal models. They worked: they eliminated the micrometastases before they could develop into detectable metastases.” Two of the three drugs are already approved for other indications, a detail that could substantially shorten the road to clinical testing.

The molecular identity of the pause is anchored to a protein called MXD4, according to the article’s title, which describes “a transient MXD4-dependent proliferative pause” that enables the survival of brain micrometastases. In practical terms, the finding means that metastatic cells in the brain are not continuously dangerous from the moment of arrival; there is a definable, mechanistically characterised stage at which they depend on specific molecular pathways to stay alive. Interfere with those pathways, and the colony collapses before it ever becomes a clinical problem. The study’s authors summarise the significance bluntly in their own words: “These findings reveal the existence of a previously unknown adaptive stage during metastatic colonisation and identify exploitable vulnerabilities to prevent brain metastasis progression and relapse.”

One of the most formidable obstacles to exploiting such a vulnerability has always been detection. Micrometastases are, by definition, too small to be seen by existing diagnostic techniques, and there are no biomarkers capable of reliably identifying patients who harbour them. The CNIO team circumvented this problem in a way that few studies have managed: by turning to human autopsy material. Through the UK-based PEACE consortium, a repository of tumour samples obtained from patients after death, the researchers gained access to metastases that had gone undetected in patients precisely because they were too small. “Thanks to PEACE, we were able to study metastases that had gone undetected in patients because they were too small,” says Valiente. “This is valuable in itself, because for the first time we have been able to assess the molecular profile of human micrometastases as they colonise the brain.”

The collaboration with PEACE also brought an emphatic endorsement from its chief investigator, Mariam Jamal-Hanjani of the UCL Cancer Institute. “Cancer spread to the brain can have devastating consequences for patients, and we know very little about the biology of this process in its earliest stages,” she said. “This study has the potential to transform our ability to intervene with targeted drugs to prevent the progression of microscopic cancer in the brain and as a result improve outcomes and quality of life in patients. It also beautifully demonstrates how we can learn from patient samples in PEACE to translate research into viable future treatment opportunities.” Her comments underscore a point that resonates throughout the study: the biology of the earliest metastatic stages has been almost entirely opaque, and autopsy-derived tissue is currently the only way to observe it directly in humans.

To move from observation to therapy, the team needed living human material as well. That came through RENACER, the Spanish National Brain Metastasis Network founded by Valiente in 2021, which is built on patients donating metastatic tissue removed during neurosurgery. These samples represent fully developed metastases, allowing the researchers to test whether the mechanisms identified in mice and in autopsy material were also operative — and druggable — in active human disease. The convergence of evidence across mouse models, post-mortem human micrometastases and living surgical samples gives the study an unusually strong translational foundation, and it is this triangulation that convinces the authors the proliferative pause is not an artefact of any single experimental system.

Perhaps the most clinically provocative finding emerged in the later stages of the research. The team discovered that the molecular processes operating during the vulnerable phase of micrometastases resemble those found at the leading edge — the invasive front — of established metastases, specifically in metastatic cells that spread by attaching themselves to the walls of blood vessels surrounding the tumour mass. This observation connects the new work to the group’s earlier research, published in EMBO Molecular Medicine, which had suggested that the cellular mechanisms involved in initiating metastasis remain active at the invasive fronts of established lesions. “We can halt the invasive fronts of human metastases using the drugs that are effective against the proliferative pause,” Valiente says. “This finding suggests that we can turn the problem around and test preventive therapies in a clinically relevant situation where there is currently no clear therapeutic strategy: preventing relapse after surgery.”

That reframing matters. Even when a primary brain metastasis is surgically removed, microscopic deposits may linger at the margins, and relapse in these situations is common and poorly served by existing options. If the same drug combination that kills micrometastases can neutralise the invasive front, surgeons and oncologists could one day administer adjuvant therapy immediately after resection, targeting residual disease while it is still in its most fragile state. The CNIO group’s medium- to long-term objective is to launch clinical trials to assess whether the drugs tested can indeed prevent brain metastasis, and the immediate focus is on preparatory work to determine which combination of the three agents produces the greatest therapeutic benefit. In parallel, the team is working to identify biomarkers that could detect micrometastases, which cannot currently be identified with existing techniques. “The combination of biomarkers and drugs that are effective against micrometastases aims to prevent their progression to the stage at which they have clinical consequences for the patient,” Valiente says.

The scale of the collaboration behind the study reflects the complexity of the questions it tackles. The National Centre for Genomic Analysis (CNAG) in Barcelona performed in situ single-cell analyses of patient samples; the US National Cancer Institute’s Center for Cancer Research in Bethesda and UT Southwestern Medical Center in Dallas contributed new models of metastatic brain disease representing the most common primary tumours; the Technical University of Dresden mapped multiple proteins in tissue samples; the Instituto de Neurociencias, CSIC-UMH, in Alicante carried out video-microscopy analyses of brain metastasis-initiating cells; and the University of Cantabria provided electron microscopy. The Francis Crick Institute and University College London, through PEACE, enabled the identification and characterisation of human brain micrometastases, while the University of Oxford and the University of Castilla-La Mancha contributed mathematical modelling of brain metastasis evolution. Multiple CNIO units, the CNIO Biobank and the Brain Metastasis Laboratory coordinated the effort. Although the study centred on the brain, the authors hypothesise that the vulnerable stage they have identified may be common to metastatic colonisation more broadly — a question they intend to pursue. “This is the beginning of the race to prevent metastasis,” Valiente says, and with an identified mechanism, approved drugs and human validation already in hand, that race now has a defined starting line.

Subject of Research: Early-stage brain metastatic colonisation and the MXD4-dependent proliferative pause as a therapeutic target

Article Title: New therapeutic strategy could open the door to preventing brain metastasis

Article References: New therapeutic strategy could open the door to preventing brain metastasis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain metastasis, micrometastases, proliferative pause, MXD4, CNIO, Cancer Cell, PEACE consortium, RENACER, metastatic colonisation, drug repurposing, cancer relapse, biomarkers